Clinical Trial Update: Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating temelimab as a disease-modifying therapy for neuropsychiatric symptoms in Post-COVID-19 syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Temelimab (temelimab)

Snippet

Sponsor: GeNeuro SA | Conditions: Post-COVID-19 Syndrome | Phase 2 | Status: COMPLETED